Dynavax releases results of hepatitis B vaccine phase-3 trial
Trial shows Heplisav demonstrated better protection of diabetes patients than approved vaccine
An experimental vaccine for hepatitis B made by Dynavax Technologies appears to work better in patients with diabetes than current treatments, the company said.
Post a Comment
Footer Content
Retail Group
Events - Retail
Industry Guides, Research & Reports
International
footer
© 2012 Drug Store News. All Rights Reserved.